Plasma Proteomics Analysis Predicts Cancer Biomarkers

Dear Colleagues,

Cancer continues to pose a significant challenge to global health, and thus its early detection and accurate diagnosis are crucial to providing effective treatment and enhanced patient outcomes. In recent years, plasma proteomics has emerged as a promising approach to identifying cancer biomarkers, which are specific molecular signatures that can indicate the presence, stage, or prognosis of cancer, and are suitable for screening, monitoring, and personalized medicine.

This Special Issue aims to showcase the latest advancements in the field of plasma proteomics and its potential to predict cancer biomarkers. We invite researchers and experts from various disciplines, including proteomics (on both mass spectrometry-based and antibody-based technologies), cancer biology, oncology, bioinformatics, and translational medicine, to contribute their original research articles, reviews, and perspectives on this topic.

We welcome contributions that attend the following areas of interest:

1. Novel plasma proteomics techniques and technologies for cancer biomarker discovery;
2. Identification and validation of plasma-based biomarkers for various types of cancers;
3. Role of plasma proteomics analysis in early cancer detection and diagnosis;
4. Functional characterization of plasma-derived cancer biomarkers;
5. Translational applications of plasma proteomics in cancer management, including prognosis, prediction, and therapeutic monitoring;
6. Integration of plasma proteomics data with other omics data for multi-dimensional cancer biomarker analysis;
7. Bioinformatics and computational approaches for data analysis and interpretation in plasma proteomics-based cancer biomarker research;
8. Challenges and opportunities in the field of plasma proteomics analysis for predicting cancer biomarkers;
9. Clinical implementation and commercialization of plasma proteomics-based cancer biomarkers;
10. Future directions and perspectives in the field of plasma proteomics analysis for cancer biomarker prediction.

We hope this Special Issue will provide a comprehensive platform for researchers to share their latest findings, insights, and perspectives on the exciting field of plasma proteomics analysis and its potential to predict cancer biomarkers.

Dr. Seong Beom Ahn
Dr. Abidali Mohamedali
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.